The startup develops next-generation cell therapies utilizing stem cell biology, immunology, and gene editing to treat cancer and autoimmune diseases. By focusing on T cells and other immune cells, the company provides stem cell-derived medicines that enhance treatment efficacy for patients facing these serious health challenges.

E INC enhances the automotive purchasing process by providing a digital platform that streamlines wholesale and retail transactions through advanced technology and data analytics. This approach addresses inefficiencies in the automotive ecosystem, enabling faster and more flexible business operations for dealers and consumers.

Gossamer Bio is a clinical‑stage biopharma developing seralutinib, an inhaled small‑molecule inhibitor of PDGFRα/β, CSF1R, and c‑KIT, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The drug is delivered via a dry‑powder inhaler to target lung tissue directly, aiming to reduce vascular inflammation, proliferation, and fibrosis while minimizing systemic side effects. Seralutinib is currently in Phase 3 trials following promising Phase 2 results.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Hemerion develops a biotechnology platform that utilizes a photosensitizing drug combined with photonics to selectively target and destroy glioblastoma cells in areas inaccessible to traditional surgery, while preserving healthy tissue. This technology addresses the critical challenge of effectively treating brain cancer, offering a promising alternative to existing therapeutic options.

This company develops novel intranasal drug delivery devices for emergency medical situations. Their devices aim to improve drug absorption and efficacy compared to traditional methods, potentially leading to better patient outcomes in critical care scenarios.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives to combat multi-drug resistant pathogens. Their proprietary formulations aim to address the urgent public health crisis posed by resistant bacterial infections, enhancing treatment options for healthcare providers.

Kezar Life Sciences develops selective immunoproteasome inhibitors to modulate immune responses in autoimmune disorders, such as lupus nephritis and autoimmune hepatitis. Their approach targets protein homeostasis to halt the secretion of disease-promoting proteins, offering a therapeutic alternative to direct immunosuppression.

Kimara transforms complex, studio-grade Generative AI workflows, often built in tools like ComfyUI, into simple, repeatable browser applications. The platform allows GenAI experts to package their advanced pipelines while providing creative teams with controlled, self-serve interfaces for asset generation. This bridges the gap between expert development and team execution, ensuring consistent, scalable output without requiring specialized technical knowledge from end-users.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

Mira develops mobile augmented reality platforms that integrate industrial wearables with software technologies to enhance operational efficiency in manufacturing environments. The company addresses the need for real-time data visualization and hands-free access to information, reducing downtime and improving worker productivity.

NevronixAI provides a digital human platform that utilizes AI-driven avatars to facilitate real-time, personalized conversations with customers across various industries. This technology addresses low engagement and conversion rates by offering 24/7 support in over 140 languages, enhancing customer confidence and reducing operational costs.

Oculi develops Software-Defined Vision Sensors to enhance AI-driven applications at the edge. Their IntelliPixel technology optimizes efficiency and maintains data privacy for commercial and defense markets. This approach delivers high-performance Vision AI with low power consumption and reduced cost.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Telo Therapeutics is developing orally bioavailable nuclear transport inhibitors, specifically TSM74, which targets XPO1 to degrade proteins involved in cancer cell signaling. This approach aims to treat cancers that are resistant to existing therapies, improving safety and efficacy by promoting rapid tumor regression in preclinical models.

Provides an AI-powered recruitment platform that automates the entire hiring process, including candidate matching, ranking, and interview scheduling. It streamlines talent acquisition for companies by reducing time-to-hire and improving candidate fit through psychometric assessments and professional genome profiling.

Twist Bioscience offers a semiconductor-based DNA synthesis platform for high-throughput, cost-effective production of custom DNA. Their technology enables rapid generation of genes, oligo pools, and variant libraries, accelerating research in synthetic biology, drug discovery, and diagnostics.

Verinos Pharma is developing Ronopterin, a selective inhibitor of inducible Nitric Oxide Synthase (iNOS), to reduce elevated brain glutamate levels and mitigate damage in patients with traumatic brain injury. This late-stage clinical drug aims to improve neurological outcomes and quality of life for individuals suffering from acute, life-threatening cerebral conditions.

Vita Therapeutics specializes in cell engineering techniques to regenerate damaged tissues and organs, utilizing precise cell manipulation to enhance recovery outcomes for patients with degenerative diseases. The company addresses the limitations of existing therapies by providing targeted cellular interventions that improve tissue repair and functionality.

Xilio Therapeutics develops tumor-activated immuno-oncology therapies using proprietary platform technology to create targeted molecules that enhance anti-tumor activity within the tumor microenvironment. This approach aims to provide effective treatment options for patients with solid tumors while minimizing systemic side effects associated with traditional immuno-oncology therapies.